$FEMY
FEMASYS INC

2024 Q1 Form 10-K Financial Statement

#000114036124016230 Filed on March 28, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $271.1K $213.1K $1.072M
YoY Change -7.77% -9.02% -11.13%
Cost Of Revenue $88.53K $78.29K $380.1K
YoY Change -15.78% -8.39% -14.0%
Gross Profit $182.6K $134.8K $691.9K
YoY Change -3.31% -9.38% -9.47%
Gross Profit Margin 67.35% 63.26% 64.54%
Selling, General & Admin $1.803M $2.421M $7.508M
YoY Change 15.59% 38.93% 25.35%
% of Gross Profit 987.52% 1795.93% 1085.15%
Research & Development $1.771M $2.071M $7.209M
YoY Change 15.17% 62.88% 23.99%
% of Gross Profit 969.69% 1536.32% 1041.87%
Depreciation & Amortization $69.98K $91.79K $483.5K
YoY Change -46.84% -31.88% -10.37%
% of Gross Profit 38.32% 68.08% 69.88%
Operating Expenses $3.645M $4.584M $15.20M
YoY Change 12.84% 45.57% 22.93%
Operating Profit -$3.463M -$4.450M -$14.51M
YoY Change 13.84% 48.3% 25.07%
Interest Expense $361.6K $43.40K $265.6K
YoY Change 21523.92% -62.18% 1872.89%
% of Operating Profit
Other Income/Expense, Net -$136.9K $0.00 $0.00
YoY Change -243.44% -100.0% -100.0%
Pretax Income -$3.600M -$4.406M -$14.24M
YoY Change 22.17% 52.57% 25.07%
Income Tax $4.340K $4.340K
% Of Pretax Income
Net Earnings -$3.600M -$4.410M -$14.25M
YoY Change 22.17% 52.39% 25.04%
Net Earnings / Revenue -1327.55% -2069.57% -1329.06%
Basic Earnings Per Share -$0.17 -$0.93
Diluted Earnings Per Share -$0.17 -$0.21 -$0.93
COMMON SHARES
Basic Shares Outstanding 22.10M 21.65M 15.38M
Diluted Shares Outstanding 21.78M 15.38M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $17.84M $21.72M $21.72M
YoY Change 75.53% 67.54% 67.54%
Cash & Equivalents $17.84M $21.72M
Short-Term Investments
Other Short-Term Assets $955.5K $695.9K $695.9K
YoY Change 76.28% 6.18% 6.18%
Inventory $971.3K $667.1K $667.1K
Prepaid Expenses
Receivables $120.5K $98.91K $98.91K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $19.88M $23.18M $23.18M
YoY Change 75.52% 64.02% 64.02%
LONG-TERM ASSETS
Property, Plant & Equipment $1.214M $3.491M $3.491M
YoY Change -11.9% 135.41% 93.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.013M $1.087M $1.087M
YoY Change 10.02% 13.4% 13.4%
Total Long-Term Assets $4.488M $4.578M $4.578M
YoY Change 76.68% 65.62% 65.62%
TOTAL ASSETS
Total Short-Term Assets $19.88M $23.18M $23.18M
Total Long-Term Assets $4.488M $4.578M $4.578M
Total Assets $24.37M $27.76M $27.76M
YoY Change 75.74% 64.28% 64.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.096M $1.138M $1.138M
YoY Change 108.01% 122.77% 122.77%
Accrued Expenses $673.5K $1.444M $1.444M
YoY Change 25.78% 216.24% 216.24%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $495.0K $406.6K $406.6K
YoY Change 62.25% -21.06% -21.06%
Total Short-Term Liabilities $2.358M $3.054M $3.054M
YoY Change 66.89% 99.9% 99.9%
LONG-TERM LIABILITIES
Long-Term Debt $6.375M $6.294M $6.294M
YoY Change 21923.27% 21923.27%
Other Long-Term Liabilities $30.39K $54.94K $54.94K
YoY Change -69.25% -43.16% -43.16%
Total Long-Term Liabilities $6.406M $6.349M $6.349M
YoY Change 6382.46% 4969.54% 4969.62%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.358M $3.054M $3.054M
Total Long-Term Liabilities $6.406M $6.349M $6.349M
Total Liabilities $8.763M $9.403M $9.403M
YoY Change 479.81% 468.84% 468.84%
SHAREHOLDERS EQUITY
Retained Earnings -$112.0M -$108.4M
YoY Change 15.35% 15.13%
Common Stock $22.22K $21.78K
YoY Change 85.3% 81.66%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $15.61M $18.35M $18.35M
YoY Change
Total Liabilities & Shareholders Equity $24.37M $27.76M $27.76M
YoY Change 75.74% 64.28% 64.28%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$3.600M -$4.410M -$14.25M
YoY Change 22.17% 52.39% 25.04%
Depreciation, Depletion And Amortization $69.98K $91.79K $483.5K
YoY Change -46.84% -31.88% -10.37%
Cash From Operating Activities -$4.568M -$3.036M -$11.28M
YoY Change 72.54% 5.86% 5.11%
INVESTING ACTIVITIES
Capital Expenditures $64.56K $44.90K $143.9K
YoY Change 625.28% -52.17% -64.68%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$90.16K -$44.90K -$143.9K
YoY Change 912.92% -52.17% -64.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $15.26M
YoY Change 19101.39%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 778.2K 16.10M 20.18M
YoY Change -640.17% -19751.64% -3060.28%
NET CHANGE
Cash From Operating Activities -4.568M -3.036M -11.28M
Cash From Investing Activities -90.16K -44.90K -143.9K
Cash From Financing Activities 778.2K 16.10M 20.18M
Net Change In Cash -3.880M 13.02M 8.754M
YoY Change 38.55% -527.89% -174.06%
FREE CASH FLOW
Cash From Operating Activities -$4.568M -$3.036M -$11.28M
Capital Expenditures $64.56K $44.90K $143.9K
Free Cash Flow -$4.633M -$3.081M -$11.42M
YoY Change 74.39% 4.02% 2.56%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;"> <tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="text-align: right; vertical-align: top; width: 18pt;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: italic; text-align: left;">(a)</div> </td> <td style="text-align: left; vertical-align: top; width: auto;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: italic;">Use of Estimates in Preparation of Financial Statements</div> </td> </tr> </table> </div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </div> <div style="margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The <span style="font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expense during the reporting periods. The most significant estimates used in these financial statements include stock options, warrants, the valuation of useful lives of property and equipment, </span>and clinical trial cost accruals<span style="font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">. Actual results could differ from those estimates.</span></div>
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
6826165
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001339005
CY2022Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://femasys.com/20231231#OperatingLeaseAndFinanceLeaseRightOfUseAsset
CY2023Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://femasys.com/20231231#OperatingLeaseAndFinanceLeaseRightOfUseAsset
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://femasys.com/20231231#OperatingAndFinanceLeaseLiabilityCurrent
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://femasys.com/20231231#OperatingAndFinanceLeaseLiabilityCurrent
CY2022Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://femasys.com/20231231#OperatingAndFinanceLeaseLiabilityNoncurrent
CY2023Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://femasys.com/20231231#OperatingAndFinanceLeaseLiabilityNoncurrent
CY2022Q4 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://femasys.com/20231231#OperatingLeaseAndFinanceLeaseRightOfUseAsset
CY2022Q4 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://femasys.com/20231231#OperatingAndFinanceLeaseLiabilityCurrent
CY2022Q4 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://femasys.com/20231231#OperatingAndFinanceLeaseLiabilityNoncurrent
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Auditor Firm
AuditorFirmId
185
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2029-04-30
CY2023 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2029-04-30
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-40492
CY2023 dei Entity Registrant Name
EntityRegistrantName
Femasys Inc.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
11-3713499
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
3950 Johns Creek Court
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Suwanee
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
GA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
30024
CY2023 dei City Area Code
CityAreaCode
770
CY2023 dei Local Phone Number
LocalPhoneNumber
500-3910
CY2023 dei Security12b Title
Security12bTitle
Common stock, par value $0.001
CY2023 dei Trading Symbol
TradingSymbol
FEMY
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
22099347
CY2023 dei Auditor Name
AuditorName
KPMG LLP
CY2023 dei Auditor Location
AuditorLocation
Atlanta, Georgia
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21716077
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12961936
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
98906
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
77470
CY2023Q4 us-gaap Inventory Net
InventoryNet
667118
CY2022Q4 us-gaap Inventory Net
InventoryNet
436723
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
695879
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
655362
CY2023Q4 us-gaap Assets Current
AssetsCurrent
23177980
CY2022Q4 us-gaap Assets Current
AssetsCurrent
14131491
CY2023Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
1212417
CY2022Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
1195637
CY2023Q4 us-gaap Property Plant And Equipment Other
PropertyPlantAndEquipmentOther
47308
CY2022Q4 us-gaap Property Plant And Equipment Other
PropertyPlantAndEquipmentOther
99344
CY2023Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
414303
CY2022Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
419303
CY2023Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
2559356
CY2022Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
2572243
CY2023Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
423077
CY2022Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
413843
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4656461
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4700370
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3545422
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3217319
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1111039
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1483051
CY2023Q4 femy Operating Lease And Finance Lease Right Of Use Asset
OperatingLeaseAndFinanceLeaseRightOfUseAsset
2380225
CY2022Q4 femy Operating Lease And Finance Lease Right Of Use Asset
OperatingLeaseAndFinanceLeaseRightOfUseAsset
319557
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
0
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3294
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1086581
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
958177
CY2023Q4 us-gaap Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment
AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment
3466806
CY2022Q4 us-gaap Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment
AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment
1281028
CY2023Q4 us-gaap Assets
Assets
27755825
CY2022Q4 us-gaap Assets
Assets
16895570
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1137823
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
510758
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1444296
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
456714
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
141298
CY2023Q4 femy Clinical Holdback Current
ClinicalHoldbackCurrent
65300
CY2022Q4 femy Clinical Holdback Current
ClinicalHoldbackCurrent
45206
CY2023Q4 femy Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
406636
CY2022Q4 femy Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
373833
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3054055
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1527809
CY2023Q4 femy Clinical Holdback Noncurrent
ClinicalHoldbackNoncurrent
54935
CY2022Q4 femy Clinical Holdback Noncurrent
ClinicalHoldbackNoncurrent
96658
CY2023Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
4258179
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0
CY2023Q4 femy Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
2036067
CY2022Q4 femy Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
28584
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
6349181
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
125242
CY2023Q4 us-gaap Liabilities
Liabilities
9403236
CY2022Q4 us-gaap Liabilities
Liabilities
1653051
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21774604
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21657381
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11986927
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11869704
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
21775
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
11987
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
117223
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
117223
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
60000
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
60000
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2787137
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
567972
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
123985306
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
108857065
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-108381629
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-94134505
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
18352589
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
15242519
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
27755825
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16895570
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1071970
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1206218
CY2023 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
380069
CY2022 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
441938
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7208701
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5813755
CY2023 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
650126
CY2022 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
558852
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6858008
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5430704
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
483481
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
561233
CY2023 us-gaap Operating Expenses
OperatingExpenses
15200316
CY2022 us-gaap Operating Expenses
OperatingExpenses
12364544
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-14508415
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-11600264
CY2023 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
431019
CY2022 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
228164
CY2023 us-gaap Interest Expense
InterestExpense
165390
CY2022 us-gaap Interest Expense
InterestExpense
13464
CY2023 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
0
CY2022 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
2306
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
265629
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
212394
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14242786
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11387870
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4338
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6300
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-14247124
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-11394170
CY2023 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-14247124
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14247124
CY2022 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-11394170
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11394170
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.96
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.96
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15384376
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15384376
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11815019
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11815019
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
26332382
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16151
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
3729
CY2022 femy Stock Issued During Period Value At The Market Offering Net Of Issuance Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingNetOfIssuanceCosts
59488
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
224939
CY2022 femy Expiration Of Warrant
ExpirationOfWarrant
0
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-11394170
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
15242519
CY2023 femy Stock Issued During Period Value Issuance Of Common Stock And Warrants
StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrants
3345996
CY2023 femy Stock Issued During Period Value At The Market Offering Net Of Issuance Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingNetOfIssuanceCosts
7423214
CY2023 femy Issuance Of Warrants In Connection With Convertible Notes
IssuanceOfWarrantsInConnectionWithConvertibleNotes
2219165
CY2023 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
4955
CY2023 femy Stock Issued During Period Value Exercise Of Pre Funded Warrants
StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants
188
CY2023 femy Stock Issued During Period Value Exercise Of Common Warrants
StockIssuedDuringPeriodValueExerciseOfCommonWarrants
3687976
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
675700
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-14247124
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
18352589
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-14247124
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-11394170
CY2023 us-gaap Depreciation
Depreciation
480187
CY2022 us-gaap Depreciation
Depreciation
539434
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3294
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
21799
CY2023 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
424504
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
327907
CY2023 us-gaap Inventory Lifo Reserve Period Charge
InventoryLIFOReservePeriodCharge
5886
CY2022 us-gaap Inventory Lifo Reserve Period Charge
InventoryLIFOReservePeriodCharge
4100
CY2023 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-47538
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-2285
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
675700
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
224939
CY2023 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
107963
CY2022 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
21436
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-6788
CY2023 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
236281
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
232553
CY2023 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-282169
CY2022 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-295862
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
627065
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
65236
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
987582
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-147073
CY2023 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-440489
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-383616
CY2023 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
22896
CY2022 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-62911
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11280546
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10731973
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
143917
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
407475
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-143917
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-407475
CY2023 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
3899813
CY2022 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0
CY2023 femy Payments Of Equity Issuance Costs
PaymentsOfEquityIssuanceCosts
547764
CY2022 femy Payments Of Equity Issuance Costs
PaymentsOfEquityIssuanceCosts
0
CY2023 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
6850000
CY2022 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
CY2023 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
525144
CY2022 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0
CY2023 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
188
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2023 femy Proceeds From Exercise Of Common Stock Warrants
ProceedsFromExerciseOfCommonStockWarrants
3687976
CY2022 femy Proceeds From Exercise Of Common Stock Warrants
ProceedsFromExerciseOfCommonStockWarrants
0
CY2023 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
4955
CY2022 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
19880
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7665066
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
59583
CY2023 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
229953
CY2022 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0
CY2023 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
0
CY2022 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
232845
CY2023 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
610340
CY2022 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
505205
CY2023 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
16193
CY2022 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
23058
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20178604
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-681645
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
8754141
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-11821093
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12961936
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24783029
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21716077
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12961936
CY2023 us-gaap Interest Paid Net
InterestPaidNet
9903
CY2022 us-gaap Interest Paid Net
InterestPaidNet
13464
CY2023 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
4550
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
5050
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2496968
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2023 femy Commission Costs Relating To Certain Proceeds From Issuance Of Common Stock
CommissionCostsRelatingToCertainProceedsFromIssuanceOfCommonStock
0
CY2022 femy Commission Costs Relating To Certain Proceeds From Issuance Of Common Stock
CommissionCostsRelatingToCertainProceedsFromIssuanceOfCommonStock
1843
CY2023 femy Prepaid Insurance Financed With Promissory Note
PrepaidInsuranceFinancedWithPromissoryNote
0
CY2022 femy Prepaid Insurance Financed With Promissory Note
PrepaidInsuranceFinancedWithPromissoryNote
141298
CY2023 femy Fair Value Of Warrants Issued In Connection With Convertible Notes
FairValueOfWarrantsIssuedInConnectionWithConvertibleNotes
2219165
CY2022 femy Fair Value Of Warrants Issued In Connection With Convertible Notes
FairValueOfWarrantsIssuedInConnectionWithConvertibleNotes
0
CY2023 femy Deferred Offering Costs Reclassified To Additional Paid In Capital
DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital
17952
CY2022 femy Deferred Offering Costs Reclassified To Additional Paid In Capital
DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital
95
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q4 femy Number Of Women Used Fem Bloc For Permanent Birth Control
NumberOfWomenUsedFemBlocForPermanentBirthControl
401
CY2023 femy Number Of Year Where Women S Used For Permanent Birth Control
NumberOfYearWhereWomenSUsedForPermanentBirthControl
P1Y
CY2023 femy Number Of Women Enrolled For Clinical Readout
NumberOfWomenEnrolledForClinicalReadout
50
CY2023 femy Number Of Women Need To Use For Interim Analysis Of Clinical Data
NumberOfWomenNeedToUseForInterimAnalysisOfClinicalData
300
CY2023 femy Period For Analysis Of Clinical Data
PeriodForAnalysisOfClinicalData
P1Y
CY2023 femy Follow Up Period For Interim Analysis Of Clinical Data
FollowUpPeriodForInterimAnalysisOfClinicalData
P5Y
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-108381629
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-14247124
CY2023 femy Proceeds From Issuance Of Debt And Equity
ProceedsFromIssuanceOfDebtAndEquity
20800182
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21716077
CY2023 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0
CY2022 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
977
CY2023Q4 femy Reserves For Uncollectible Accounts
ReservesForUncollectibleAccounts
2000
CY2022Q4 femy Reserves For Uncollectible Accounts
ReservesForUncollectibleAccounts
2048
CY2023 femy Inventory Disposals
InventoryDisposals
4409
CY2022 femy Inventory Disposals
InventoryDisposals
2847
CY2023Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
3580
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
2103
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
367934
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
244498
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
128993
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
100453
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
170191
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
91772
CY2023Q4 us-gaap Inventory Net
InventoryNet
667118
CY2022Q4 us-gaap Inventory Net
InventoryNet
436723
CY2023Q4 femy Research Tax Credits
ResearchTaxCredits
928234
CY2022Q4 femy Research Tax Credits
ResearchTaxCredits
891062
CY2023Q4 femy Research Tax Credits Current
ResearchTaxCreditsCurrent
224000
CY2022Q4 femy Research Tax Credits Current
ResearchTaxCreditsCurrent
212134
CY2023Q4 femy Research Tax Credits Noncurrent
ResearchTaxCreditsNoncurrent
704234
CY2022Q4 femy Research Tax Credits Noncurrent
ResearchTaxCreditsNoncurrent
678928
CY2023Q4 femy Research Tax Credits
ResearchTaxCredits
928234
CY2022Q4 femy Research Tax Credits
ResearchTaxCredits
891062
CY2023 us-gaap Depreciation Expense On Reclassified Assets
DepreciationExpenseOnReclassifiedAssets
468391
CY2022 us-gaap Depreciation Expense On Reclassified Assets
DepreciationExpenseOnReclassifiedAssets
521151
CY2023 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
187826
CY2023 us-gaap Property Plant And Equipment Gross Period Increase Decrease
PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease
47538
CY2022 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
28234
CY2022 us-gaap Property Plant And Equipment Gross Period Increase Decrease
PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease
2285
CY2023 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023 femy Minimum Term To Record Operating Leases As Right To Use Assets And Operating Lease Liabilities
MinimumTermToRecordOperatingLeasesAsRightToUseAssetsAndOperatingLeaseLiabilities
P1Y
CY2023 femy Minimum Term To Record Finance Leases As Right To Use Assets And Finance Lease Liabilities
MinimumTermToRecordFinanceLeasesAsRightToUseAssetsAndFinanceLeaseLiabilities
P1Y
CY2022Q4 femy Accrued Clinical Trial Cost
AccruedClinicalTrialCost
333440
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
60210
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
0
CY2023Q4 femy Franchise Taxes
FranchiseTaxes
12160
CY2022Q4 femy Franchise Taxes
FranchiseTaxes
26886
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
13179
CY2023Q4 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P3Y
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1668951
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1668951
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1668951
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1665657
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
0
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3294
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3294
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
21799
CY2022 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
232845
CY2022Q3 femy Authorized Offering Amount Of Securities
AuthorizedOfferingAmountOfSecurities
150000000
CY2022Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
150000000
CY2023Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
17952
CY2022Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
95
CY2023Q4 femy Deferred Offering Costs Capitalized
DeferredOfferingCostsCapitalized
214798
CY2022Q4 femy Deferred Offering Costs Capitalized
DeferredOfferingCostsCapitalized
232750
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1082606
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
85191
CY2023Q4 femy Accrued Clinical Trial Cost
AccruedClinicalTrialCost
276141
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
11197
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1444296
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
456714
CY2022Q4 femy Clinical Holdback Liability
ClinicalHoldbackLiability
141864
CY2023 femy Clinical Holdback Retained
ClinicalHoldbackRetained
5900
CY2023 femy Clinical Holdback Paid
ClinicalHoldbackPaid
27529
CY2023Q4 femy Clinical Holdback Liability
ClinicalHoldbackLiability
120235
CY2023Q4 femy Clinical Holdback Current
ClinicalHoldbackCurrent
65300
CY2023Q4 femy Clinical Holdback Noncurrent
ClinicalHoldbackNoncurrent
54935
CY2021Q4 femy Clinical Holdback Liability
ClinicalHoldbackLiability
168738
CY2022 femy Clinical Holdback Retained
ClinicalHoldbackRetained
21456
CY2022 femy Clinical Holdback Paid
ClinicalHoldbackPaid
48330
CY2022Q4 femy Clinical Holdback Liability
ClinicalHoldbackLiability
141864
CY2022Q4 femy Clinical Holdback Current
ClinicalHoldbackCurrent
45206
CY2022Q4 femy Clinical Holdback Noncurrent
ClinicalHoldbackNoncurrent
96658
CY2022 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
CY2023 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
CY2022Q4 femy Contract With Customer Unsatisfied Performance Obligation
ContractWithCustomerUnsatisfiedPerformanceObligation
0
CY2023Q4 femy Contract With Customer Unsatisfied Performance Obligation
ContractWithCustomerUnsatisfiedPerformanceObligation
0
CY2023 femy Percentage Of Restocking Fee
PercentageOfRestockingFee
0.30
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 18pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </td> <td style="width: 18pt; vertical-align: top; font-style: italic; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(s)</td> <td style="width: auto; vertical-align: top;"> <div style="font-style: italic; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Concentration of Credit Risk</div> </td> </tr> </table> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </div> <div style="margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, and accounts receivable. As of December 31, 2022, the Company maintained substantially all its cash and cash equivalents primarily in one bank, Silicon Valley Bank (SVB), in amounts which, at times, exceed federally insured limits, which Management believed, at that time, SVB was financially sound and minimal credit risk existed with respect to these holdings. As of March 15, 2023, the Company transferred substantially all of its cash and cash equivalents to another financial institution, Wells Fargo Bank.</span></div> <div style="margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> </span><br/> <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">The Company generates revenue from sales directly to U.S. customers and to the Company’s international distributors with all prices in U.S. dollars. For the year ended December 31, 2022, Bayer Yakuhin, Ltd. accounted </span>for 10% <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">of total revenue. No other customers accounted for more than 10% of total revenue for the year ended December 31, 2023. As of December 31, 2023 and 2022, the Company had two customers and one customer, respectively, with accounts receivable balances greater than 10% of total receivables. The balances for these customers were 19% and 11% as of December 31, 2023 and 10% as of December 31, 2022</span>.</div>
CY2023 us-gaap Advertising Expense
AdvertisingExpense
18738
CY2022 us-gaap Advertising Expense
AdvertisingExpense
41022
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
0
CY2022 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
0
CY2023 femy Number Of Extension Option For Operating Lease Term
NumberOfExtensionOptionForOperatingLeaseTerm
1
CY2023 femy Lessee Operating Lease Option To Extend Term
LesseeOperatingLeaseOptionToExtendTerm
P5Y
CY2023 us-gaap Operating Lease Expense
OperatingLeaseExpense
47029
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2380225
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
307761
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
406636
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
357640
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2036067
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28584
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2442703
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
386224
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y3M18D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y1M6D
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
469995
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
485598
CY2023 us-gaap Short Term Lease Cost
ShortTermLeaseCost
6917
CY2022 us-gaap Short Term Lease Cost
ShortTermLeaseCost
5730
CY2023 us-gaap Variable Lease Cost
VariableLeaseCost
78367
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
41198
CY2023 us-gaap Lease Cost
LeaseCost
555279
CY2022 us-gaap Lease Cost
LeaseCost
532526
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
451750
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
629340
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
654514
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
680694
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
707922
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
243835
CY2023Q4 femy Operating Lease Liability To Be Paid
OperatingLeaseLiabilityToBePaid
3368055
CY2023Q4 femy Lessee Operating Lease And Finance Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount
925352
CY2023Q4 femy Operating And Finance Lease Liability
OperatingAndFinanceLeaseLiability
2442703
CY2023Q4 femy Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
406636
CY2023Q4 femy Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
2036067
CY2022Q4 us-gaap Finance Lease Right Of Use Asset Before Accumulated Amortization
FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
150122
CY2022Q4 us-gaap Finance Lease Right Of Use Asset Accumulated Amortization
FinanceLeaseRightOfUseAssetAccumulatedAmortization
138326
CY2022Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
11796
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
16193
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
0
CY2022Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
16193
CY2022Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.10
CY2022Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P0Y8M12D
CY2023 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
11796
CY2022 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
18283
CY2023 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
599
CY2022 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
2892
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
4338
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
6300
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
4338
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
6300
CY2023 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-3326982
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-2797001
CY2023 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-70586
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
371982
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3397568
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2425019
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4338
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6300
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0
CY2022 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0
CY2023 femy Effective Income Tax Rate Reconciliation Tax Credit Reduction Research Percent
EffectiveIncomeTaxRateReconciliationTaxCreditReductionResearchPercent
0.02
CY2022 femy Effective Income Tax Rate Reconciliation Tax Credit Reduction Research Percent
EffectiveIncomeTaxRateReconciliationTaxCreditReductionResearchPercent
-0.01
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.01
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.01
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.24
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.21
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
19675117
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
17869574
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
13172
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
7625
CY2023Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
86603
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
90508
CY2023Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
77447
CY2022Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
41279
CY2023Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2613867
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1487512
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3390709
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3088254
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
176065
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
46312
CY2023Q4 femy Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
536430
CY2022Q4 femy Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
90224
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1479
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1189
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
26570889
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
22722477
CY2023Q4 femy Deferred Tax Liabilities Uniform Capitalization
DeferredTaxLiabilitiesUniformCapitalization
10513
CY2022Q4 femy Deferred Tax Liabilities Uniform Capitalization
DeferredTaxLiabilitiesUniformCapitalization
10733
CY2023Q4 femy Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
522710
CY2022Q4 femy Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
71646
CY2023Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
0
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
0
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
533223
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
82379
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
26037666
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
22640098
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3397568
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2425019
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15384376
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15384376
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11815019
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11815019
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
CY2023Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
90380015
CY2017Q1 femy Number Of Shares Authorized For All Classes Of Stock
NumberOfSharesAuthorizedForAllClassesOfStock
169000000
CY2017Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.001
CY2023 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3300000
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7700000
CY2023Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
3899813
CY2023Q2 femy Placement Agent Fees Expenses And Offering Expenses
PlacementAgentFeesExpensesAndOfferingExpenses
547764
CY2023 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1318000
CY2023Q4 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2023Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
3899813
CY2023Q2 femy Payments Of Equity Issuance Costs
PaymentsOfEquityIssuanceCosts
547764
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1133480
CY2023Q2 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
3352049
CY2023Q3 femy Proceeds From Exercise Of Common Stock Warrants
ProceedsFromExerciseOfCommonStockWarrants
3687976
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
11912435
CY2022Q2 femy Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
11112
CY2023 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2021Q2 femy Number Of Equity Incentive Plans
NumberOfEquityIncentivePlans
2
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1301200
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
367670
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.96
CY2022 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-11394170
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11394170
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3306
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2102030
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y8M8D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1226458
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
2.65
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y2M1D
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P10Y
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
675700
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
224939
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
849834
CY2023 femy Share Based Compensation Expense To Be Recognized Upon Achieving Certain Performance Condition
ShareBasedCompensationExpenseToBeRecognizedUponAchievingCertainPerformanceCondition
155222
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
694612
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y
CY2023 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
75202
CY2022 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
73947
CY2023Q4 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
5000000
CY2023 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
138000
CY2022 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
0
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14247124
CY2023 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-14247124
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.96
CY2023 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2252030
CY2022 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1081550
CY2023 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
233460
CY2022 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
233460
CY2023 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
14164465
CY2022 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1315010
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
0001140361-24-016230-index-headers.html Edgar Link pending
0001140361-24-016230-index.html Edgar Link pending
0001140361-24-016230.txt Edgar Link pending
0001140361-24-016230-xbrl.zip Edgar Link pending
ef20015354_10k.htm Edgar Link pending
ef20015354_ex23-1.htm Edgar Link pending
ef20015354_ex31-1.htm Edgar Link pending
ef20015354_ex31-2.htm Edgar Link pending
ef20015354_ex32-1.htm Edgar Link pending
ef20015354_ex32-2.htm Edgar Link pending
ef20015354_ex97-1.htm Edgar Link pending
femy-20231231.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image00001.jpg Edgar Link pending
image00002.jpg Edgar Link pending
image00003.jpg Edgar Link pending
image00004.jpg Edgar Link pending
image00005.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
femy-20231231_cal.xml Edgar Link unprocessable
femy-20231231_def.xml Edgar Link unprocessable
femy-20231231_lab.xml Edgar Link unprocessable
femy-20231231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ef20015354_10k_htm.xml Edgar Link completed
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending